15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Barinthus Biotherapeutics plc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $4.00 to $4.00, so the covering firms are broadly aligned. The average target of $4.00 sits 441% above the current $0.74. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.27 next quarter toward $-1.14 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Barinthus Biotherapeutics plc.
As of Sep, 1 of 1 firms rate BRNS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BRNS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.27
Range $-0.27 – $-0.26 · 2 analysts · -2% YoY
Next period, 2 analysts expect Barinthus Biotherapeutics plc to earn $-0.27 a share (range $-0.27 – $-0.26), versus $-0.27 a year earlier. Full-year consensus is $-0.92, growing to $-1.14 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Barinthus Biotherapeutics plc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BRNS.
#1
Yi Chen
HC Wainwright & Co. · Rank #277
Buy
$4.00+440.5% to target
Overall win rate
33%
+ Follow
#2
James Molloy
Alliance Global Partners · Rank #454
Buy
$7.00+845.9% to target
Overall win rate
25%
+ Follow
#3
AH
Andy Hsieh
William Blair
Buy
No targeton BRNS
Coverage
—
+ Follow
BRNS stock forecast FAQ
What is BRNS's average 12-month price target?+
The 1 analysts with a live target average $4.00 for Barinthus Biotherapeutics plc over the next 12 months, ranging from a $4.00 high to a $4.00 low.
Is BRNS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover BRNS?+
1 analysts have an active rating on Barinthus Biotherapeutics plc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering BRNS?+
Among analysts who currently cover BRNS, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #277). Their current call is Buy with a $4.00 target.
What is Barinthus Biotherapeutics plc's projected EPS for next quarter?+
The consensus estimate is $-0.27 per share (range $-0.27 – $-0.26) across 2 analysts. Full-year EPS is projected at $-0.92, rising to $-1.14 the following year.
How much revenue is Barinthus Biotherapeutics plc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading BRNS lately?+
As of Sep, 1 of 1 firms rate BRNS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BRNS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
